Efficacy Evaluation of Shen Cao Gan Jiang Tang on Mild and Moderate COVID-19 Patients

NCT05055427 | Completed Phase 2

• 1 other identifier: 458/HĐĐĐ-ĐHYD
• Study Type: interventional
• Target: 300
• Locations: 1 country
• Sites: 1

Brief Summary

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes COVID-19 (coronavirus disease 2019). Patients with COVID-19 may experience various clinical manifestations, from no symptoms to critical illness such as severe pneumonia and acute respiratory distress syndrome (ADRS). So far, there is no specific medication for COVID-19; hence, the current available treatments mostly aim at symptoms management and supportive care. From traditional medicine perspective, COVID-19 is classified as warm-disease (Wen-yi). The main points of treatment for COVID-19 in early stage based on traditional medicine perspective are strengthen the Protective Qi (Wei Qi - the body immune system), and restore the balance of Qi, which is vital biological energy to prevent the invasion of external pathogens, including the SARS-CoV-2 virus. The Shen Cao Gan Jiang Tang have including Gan Cao Gan Jiang Tang (GGT) with the addition of Ginseng. This formula is originated from Shang Han Lun (Treatise on Febrile Diseases Caused by Cold) by Zhang Zhong-jing, used to enhance the Protective Qi, treat the early stage of Febrile Diseases, This clinical trial aims to evaluate the efficacy of the Shen Cao Gan Jiang Tang on mild and moderate COVID-19 patients

Conditions

COVID-19 Respiratory Infection; Herbal Medicine

Outcome Measures

Primary Outcomes (5)

• Duration of symptoms of COVID-19

  Time (days) from randomization to symptoms disappear

  From Day 1 to Day 21 after randomization

• The severity of the COVID-19 total and individual symptoms

  Time (days) from randomization to the relief of total and individual COVID-19 symptoms scores

  From Day 1 to Day 21 after randomization

• Rate of progression to disease severity

  Number of patients (%) progressed to severe level of COVID-19 severity scale based on the Vietnam Ministry of Health severity scale during the period of the treatment

  During inpatient treatment, maximum to Day 21 after randomization

• The time required to meet discharge standards

  Time (days) from randomization to get required for a negative real-time polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 or CT \> 30

  During inpatient treatment, maximum to Day 21 after randomization

• National Early Warning Score 2 (NEWS2)

  Assessed by National Early Warning Score 2 (NEWS2)

  During inpatient treatment, maximum to Day 21 after randomization

Secondary Outcomes (6)

• Cycle threshold (CT)

  During inpatient treatment, maximum to Day 21 after randomization

• Duration of SARS-CoV-2 virus infection

  During inpatient treatment, maximum to Day 21 after randomization

• Mortality rate

  From Day 1 to Day 21 after randomization

• Number of participants clinically recovered

  From Day 1 after randomisation to Day for patients meet discharge criteria

• Paracetamol/Ibuprofen intake

  From Day 1 after randomisation to Day for patients meet discharge criteria

Study Arms (2)

• Experimental: Investigational arm

EXPERIMENTAL

Patients take Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng) and the Standard of Care (SOC) for the treatment of COVID-19 based on the Vietnam Ministry of Health guideline.

Drug: Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng)

• Controlled arm

NO INTERVENTION

Patients receive the Standard of Care (SOC) for the treatment of COVID-19 based on the Vietnam Ministry of Health guideline

Interventions

Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng) DRUG

Patients take Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng), one bag of decoction (90ml) two times a day for 10 days. In additional, patients also receive the Standard of Care (SOC) for the treatment of COVID-19 based on the Vietnam Ministry of Health guideline. Ingredients per formula (tang): 12 grams of honey-fried Radix Glycyrrhizae, 6 grams of Rhizoma Zingiberis (stir-baked), 6 grams of Panax Ginseng. The decoction of concentrated extract is packed into aluminum foil vacuum bag, 90ml per bag, 1 formula (tang) is equivalent to 2 bags. Patients use the decoction directly from the bag. Daily dose: 1 bag per time, 2 times per day

Also known as: "Sâm Thảo Can khương thang (Cam thảo Can khương gia Nhân sâm)"

• Experimental: Investigational arm

Eligibility Criteria

• Age: 18 Years - 64 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• From full 18 to 64 years old;
• The patient was diagnosed with SARS-CoV-2 infection by RT-PCR confirmation (+) and CT \< 30.
• Patients classified as mild (acute upper respiratory tract infection): patients infected with SARS-CoV-2 early in the first 5 days from the time of having one of the non-specific clinical symptoms such as fever, cough dry, sore throat, stuffy nose, fatigue, headache, muscle pain, decreased taste, decreased sense of smell. And there are no signs of pneumonia or hypoxia, respiratory rate ≤ 20 times/min, Saturation of Peripheral Oxygen (SpO2) ≥ 96% when breathing air.
• Patients classified as moderate (Pneumonia): patients infected with SARS-CoV-2 in the first 10 days from the time of having one of the non-specific clinical symptoms, showing signs of pneumonia (fever, cough, dyspnea, tachypnea \>20 breaths/min) and no signs of severe pneumonia, Saturation of Peripheral Oxygen (SpO2) ≥ 93% when breathing air.
• Inpatient treatment
• Subjects do not use any other medicines with herbal ingredients for underlying conditions or any other purposes;
• Voluntary participation in the study by signing an informed consent
• Patients who have not been vaccinated or have just received 1 dose of COVID-19 vaccine

You may not qualify if:

• Severe or critical COVID-19 based on the COVID-19 severity scale of Vietnam Ministry of Health;
• Chronic obstructive pulmonary disease, kidney failure requiring dialysis or creatinine ≥ 2.0mg/dl through medical history; parenteral or parenteral nutrition, uncontrolled type 2 diabetes (HbA1c \> 7%), uncontrolled hypertension (value \> 160/100 mmHg), uncontrolled coronary artery disease (new/currently established) requires medication adjustment), heart failure, neurological disease (eg, acute stroke, polyneuritis within 1 month) or mental illness, active tuberculosis, active autoimmune disease;
• Have a chronically weakened immune system (AIDS, cancer, undergoing chemotherapy-radiotherapy in the past six months, immunosuppressive disease);
• Taking immunosuppressive drugs (e.g., anti-rejection treatment after organ transplant or blood stem cell transplant);
• Allergic to products that contain ginseng;
• Pregnant or lactating women;
• Already participating in another clinical trial;
• The patient has received 2 doses of COVID-19 vaccine.

Sponsors & Collaborators

• University of Medicine and Pharmacy at Ho Chi Minh City: lead

Study Sites (1)

University of Medicine and Pharmacy at Ho Chi Minh City

Ho Chi Minh City, 700000, Vietnam

Location

MeSH Terms

Interventions

Asian ginseng

Study Officials

• Van-Dan Nguyen, MD

  University of Medicine and Pharmacy at Ho Chi Minh City

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Masking Details: An open-label study was conducted because of the urgency of major public health events
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Model Details: This is a prospective, open-label, randomized controlled trial, we recruited patients with Covid-19 from five temporary for COVID-19 treatment in Ho Chi Minh City, Viet Nam. The protocol was designed based on the Good Clinical Practice guidelines and The Declaration of Helsinki. Number of Participants have 150 mild COVID-19 patient and 150 moderate COVID-19 patient. In each group of mild or moderate patients, we plan to randomize in a 1:1 ratio. Subjects in the investigational group will receive Shen Cao Gan Jiang Tang in addition to the Standard of Care (SOC) for the treatment of COVID-19 based on the Vietnam Ministry of Health guideline. Subjects in the controlled group will receive the Standard of Care (SOC) for the treatment of COVID-19 based on the Vietnam Ministry of Health guideline.

Study Record Dates

• First Submitted: September 21, 2021
• First Posted: September 24, 2021
• Study Start: August 20, 2021
• Primary Completion: December 25, 2021
• Study Completion: December 25, 2021
• Last Updated: May 31, 2023

Record last verified: 2023-05

Data Sharing

• IPD Sharing: Will not share

Locations

VN (1)